Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christiane Pott

Showing results (31-40 of 114) with videos related to

Pageof 12
Sort By:
Annals of Hematology|December 17, 2013
Long-term clinical and molecular remissions in patients with mantle cell lymphoma following high-dose therapy and autologous stem cell transplantationBernd Metzner, Thomas H Müller, Wolfgang Gebauer, et al.
European Journal of Haematology|April 24, 2023
Long-term outcome in patients with mantle cell lymphoma following high-dose therapy and autologous stem cell transplantationBernd Metzner, Thomas H Müller, Jochen Casper, et al.
Frontiers in Immunology|March 4, 2026
Non-ICANS neurotoxicities CD19-directed CAR T-cell therapy and the emergence of movement and neurocognitive treatment-emergent adverse events: a case reportTorsten Schroeder, Guranda Chitadze, Justina Dargvainiene, et al.
Blood|July 31, 2004
The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study GroupRoswitha Forstpointner, Martin Dreyling, Roland Repp, et al.
BMC Cancer|August 25, 2025
The MCL elderly III trial protocol: an international, randomized, open-label phase II trial to investigate the combinations of venetoclax, ibrutinib and rituximab or bendamustine, ibrutinib and rituximab in patients with treatment naive mantle cell lymphoma not eligible for dose-intensive treatmentStephanie Herold, Christian Schmidt, Carlo Visco, et al.
Leukemia|October 28, 2025
ctDNA dynamics demonstrates rapid treatment response to tafasitamab + R-CHOP +/- lenalidomide and predicts outcome in diffuse large B-cell lymphoma: results from the phase 1b First-MIND studyMouhamad Khouja, Britta Kehden, Derek Blair, et al.
Blood|June 19, 2004
Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCRMatthias Ritgen, Stephan Stilgenbauer, Nils von Neuhoff, et al.
Annals of Hematology|May 11, 2021
Reduction of immunosuppression combined with whole-brain radiotherapy and concurrent systemic rituximab is an effective yet toxic treatment of primary central nervous system post-transplant lymphoproliferative disorder (pCNS-PTLD): 14 cases from the prospective German PTLD registryHeiner Zimmermann, Mirko Nitsche, Christiane Pott, et al.
Blood|September 2, 2006
Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG)Roswitha Forstpointner, Michael Unterhalt, Martin Dreyling, et al.
Blood|December 8, 2005
Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphomaChristiane Pott, Carsten Schrader, Stefan Gesk, et al.
Pageof 12

Showing results (31-40 of 114) with videos related to

Sort By:
Pageof 12
Annals of Hematology|December 17, 2013
Long-term clinical and molecular remissions in patients with mantle cell lymphoma following high-dose therapy and autologous stem cell transplantationBernd Metzner, Thomas H Müller, Wolfgang Gebauer, et al.
European Journal of Haematology|April 24, 2023
Long-term outcome in patients with mantle cell lymphoma following high-dose therapy and autologous stem cell transplantationBernd Metzner, Thomas H Müller, Jochen Casper, et al.
Frontiers in Immunology|March 4, 2026
Non-ICANS neurotoxicities CD19-directed CAR T-cell therapy and the emergence of movement and neurocognitive treatment-emergent adverse events: a case reportTorsten Schroeder, Guranda Chitadze, Justina Dargvainiene, et al.
Blood|July 31, 2004
The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study GroupRoswitha Forstpointner, Martin Dreyling, Roland Repp, et al.
BMC Cancer|August 25, 2025
The MCL elderly III trial protocol: an international, randomized, open-label phase II trial to investigate the combinations of venetoclax, ibrutinib and rituximab or bendamustine, ibrutinib and rituximab in patients with treatment naive mantle cell lymphoma not eligible for dose-intensive treatmentStephanie Herold, Christian Schmidt, Carlo Visco, et al.
Leukemia|October 28, 2025
ctDNA dynamics demonstrates rapid treatment response to tafasitamab + R-CHOP +/- lenalidomide and predicts outcome in diffuse large B-cell lymphoma: results from the phase 1b First-MIND studyMouhamad Khouja, Britta Kehden, Derek Blair, et al.
Blood|June 19, 2004
Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCRMatthias Ritgen, Stephan Stilgenbauer, Nils von Neuhoff, et al.
Annals of Hematology|May 11, 2021
Reduction of immunosuppression combined with whole-brain radiotherapy and concurrent systemic rituximab is an effective yet toxic treatment of primary central nervous system post-transplant lymphoproliferative disorder (pCNS-PTLD): 14 cases from the prospective German PTLD registryHeiner Zimmermann, Mirko Nitsche, Christiane Pott, et al.
Blood|September 2, 2006
Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG)Roswitha Forstpointner, Michael Unterhalt, Martin Dreyling, et al.
Blood|December 8, 2005
Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphomaChristiane Pott, Carsten Schrader, Stefan Gesk, et al.
Pageof 12